IGM Biosciences, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Mary Beth Harler
- Full Time Employees
- 149
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 325 East Middlefield Road Mountain View CA United States of America 94043
- IPO Date
- Sep 18, 2019
- CIK
- 0001496323
- Website
- igmbio.com
- Similar Companies
- Business
- IGM Biosciences, Inc. is a clinical-stage biotechnology company that develops engineered IgM antibodies leveraging its proprietary IgM platform, which enables antibodies with 10 binding sites for enhanced selectivity, affinity, and avidity compared to conventional IgG antibodies with two binding sites; the platform supports T cell engagers, receptor cross-linking agonists, and targeted cytokines for oncology, autoimmune, and inflammatory diseases. Core product candidates include imvotamab (IGM-2323), a bispecific CD20 x CD3 T cell engaging IgM antibody in Phase 1b trials for severe systemic lupus erythematosus and rheumatoid arthritis; aplitabart (IGM-8444), a DR5 agonist IgM antibody in a randomized Phase 2 trial with FOLFIRI and bevacizumab for second-line metastatic colorectal cancer; and earlier-stage assets such as IGM-2644 (CD38 x CD3 bispecific T cell engager), IGM-7354 (IL-15 x PD-L1), and IGM-2537 (CD123 x CD3). The company, founded in 2010 and headquartered in Mountain View, California, conducts research and clinical development primarily in the United States with a focus on patients suffering from hard-to-treat cancers and autoimmune conditions. In July 2025, IGM Biosciences entered a definitive merger agreement to be acquired by Concentra Biosciences, LLC for $1.247 per share in cash plus a contingent value right, with a tender offer to commence by July 16, 2025, and closing anticipated in August 2025 subject to majority shareholder tender and other conditions; this follows a 2023 strategic pipeline prioritization emphasizing colorectal cancer via DR5 agonists and autoimmune diseases via T cell engagers, including workforce reduction and halting certain hematologic oncology programs.
IGM Biosciences, Inc. (IGMS) Q2 Earnings and Revenues Surpass Estimates
IGMS Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of IGM Biosciences, Inc. is Fair to Shareholders
IGM Biosciences Enters into Agreement to Be Acquired by Concentra Biosciences for $1.247 in Cash per Share Plus a Contingent Value Right
IGM Biosciences, Inc. (IGMS) Reports Q1 Loss, Misses Revenue Estimates
IGM Biosciences, Inc. (IGMS) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
Down -76.91% in 4 Weeks, Here's Why IGM Biosciences (IGMS) Looks Ripe for a Turnaround
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of IGM Biosciences, Inc. - IGMS
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of IGM Biosciences, Inc. - IGMS
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of IGM Biosciences, Inc. - IGMS
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of IGM Biosciences, Inc. - IGMS
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of IGM Biosciences, Inc. - IGMS
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of IGM Biosciences, Inc. - IGMS
IGMS STOCK ALERT: Levi & Korsinsky Notifies IGM Biosciences, Inc. Investors of an Ongoing Investigation
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of IGM Biosciences, Inc. - IGMS
IGM Biosciences downgraded to Hold from Buy at Stifel
IGM Biosciences downgraded to Underweight from Equal Weight at Morgan Stanley
IGM Biosciences downgraded to Market Perform from Outperform at BMO Capital
IGM Biosciences to cut 73% of workforce as latest pivot fails to pan out
IGM Biosciences Provides Strategic Update on Autoimmunity Pipeline Programs
IGM Biosciences, Inc. (IGMS) Reports Q3 Loss, Tops Revenue Estimates